The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery

Recruiting now · Not applicable

Conditions studied: Red Blood Cell Transfusion

In brief

The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.

Key facts

Study ID: NCT06230198
Run by: Population Health Research Institute
People needed: 4500
Starts: 2024-12-04
Expected to finish: 2026-11-01
Last updated by the study team: 2025-03-04

Who can join

Age: 10 and older, up to 110. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Hospitals completing >200 adult cardiac surgical cases a year; (ii) 95% of cardiovascular surgery group (i.e., cardiac anesthesiologists, surgeons, and perfusionists) agree to manage patients under both autologous priming policies as per their randomization schedule for the duration of the trial.
All patients undergoing cardiac surgery on cardiopulmonary bypass at an enrolled site during the trial period will be included in data collection.

You may not qualify if…

Complete <=200 cardiac surgical cases.
<95% of their cardiovascular surgery group agrees to manage patients according to either of the two policies.

Where it is running

St. Boniface Hospital — Winnipeg, Manitoba, Canada (enrolling)
Hamilton General Hospital — Hamilton, Ontario, Canada (enrolling)
Montreal Heart Institute — Montreal, Quebec, Canada (enrolling)
Centre Hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.